Idiopathic normal-pressure hydrocephalus Pathophysiology and diagnosis by CSF biomarkers

Neurology

Volumn 80, Issue 15, 2013, Pages 1385-1392

  Jeppsson, Anna ^a   Zetterberg, Henrik ^b,c   Blennow, Kaj ^b   Wikkelsø, Carsten ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; MYELIN PROTEIN; NEUROFILAMENT PROTEIN; SYNAPSIN I; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; NORMOTENSIVE HYDROCEPHALUS; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

AGED; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; MIDDLE AGED; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEINS; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 84876261561     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828c2fda     Document Type: Article

References (39)

1. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure: observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 1965; 2: 307-327.
2. Blomsterwall E, Bilting M, Stephensen H, Wikkelso C. Gait abnormality is not the only motor disturbance in normal pressure hydrocephalus. Scand J Rehabil Med 1995; 27: 205-209.
3. Hellström P, Edsbagge M, Archer T, Tisell M, Tullberg M, Wikkelso C. The neuropsychology of patients with clinically diagnosed idiopathic normal pressure hydrocephalus. Neurosurgery 2007; 61: 1219-1226.
4. Tanaka N, Yamaguchi S, Ishikawa H, Ishii H, Meguro K. Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan: the Osaki-Tajiri project. Neuroepidemiology 2009; 32: 171-175.
5. Klinge P, Hellstrom P, Tans J, Wikkelso C. One-year outcome in the European multicentre study on iNPH. Acta Neurol Scand 2012; 126: 145-153.
6. Marmarou A, Bergsneider M, Klinge P, Relkin N, Black P. The value of supplemental prognostic tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57(3 suppl):S17-S28; discussion ii-v.
7. Agren-Wilsson A, Lekman A, Sjoberg W, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007; 116: 333-339.
8. Tarnaris A, Toma AK, Kitchen ND, Watkins LD. Ongoing search for diagnostic biomarkers in idiopathic normal pressure hydrocephalus. Biomark Med 2009; 3: 787-805.
9. Tarnaris A, Toma AK, Chapman MD, et al. The longitudinal profile of CSF markers during external lumbar drainage. J Neurol Neurosurg Psychiatry 2009; 80: 1130-1133.
10. Tarnaris A, Toma AK, Chapman MD, Keir G, Kitchen ND, Watkins LD. Use of cerebrospinal fluid amyloid-beta and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus. J Neurosurg 2011; 115: 145-150.
11. Tullberg M, Blennow K, Mansson JE, Fredman P, Tisell M, Wikkelso C. Ventricular cerebrospinal fluid neurofilament protein levels decrease in parallel with white matter pathology after shunt surgery in normal pressure hydrocephalus. Eur J Neurol 2007; 14: 248-254.
12. Patel S, Lee EB, Xie SX, et al. Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 2012; 9: 7.
13. Tullberg M, Blennow K, Mansson JE, Fredman P, Tisell M, Wikkelso C. Cerebrospinal fluid markers before and after shunting in patients with secondary and idiopathic normal pressure hydrocephalus. Cerebrospinal Fluid Res 2008; 5: 9.
14. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998; 50: 1122-1127.
15. Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 1970; 167: 379-387.
16. Sutton LN, Wood JH, Brooks BR, Barrer SJ, Cohen SR. Cerebrospinal fluid myelin basic protein in hydrocephalus. J Neurosurg 1983; 59: 467-470.
17. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
18. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 1989; 37: 209-215.
19. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 2010; 30: 459-473.
20. Mattsson N, Tabatabaei S, Johansson P, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011; 13: 151-159.
21. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57(3 suppl):S4-S16; discussion ii-v.
22. Marmarou A, Bergsneider M, Relkin N, Klinge P, Black P. Development of guidelines for idiopathic normal-pressure hydrocephalus: introduction. Neurosurgery 2005; 57(3 suppl): S1-S3; discussion ii-v.
23. Hellstrom P, Klinge P, Tans J, Wikkelso C. A new scale for assessment of severity and outcome in iNPH. Acta Neurol Scand 2012; 126: 229-237.
24. Edsbagge M, Starck G, Zetterberg H, Ziegelitz D, Wikkelso C. Spinal cerebrospinal fluid volume in healthy elderly individuals. Clin Anat 2011; 24: 733-740.
25. Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008; 65: 1102-1107.
26. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-345.
27. Tarnaris A, Toma AK, Pullen E, et al. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus. Alzheimers Dement 2011; 7: 501-508.
28. Ray B, Reyes PF, Lahiri DK. Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloidbeta (Abeta) peptide and phospho-tau. J Psychiatr Res 2011; 45: 539-547.
29. Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology 2008; 71: 202-209.
30. Momjian S, Owler BK, Czosnyka Z, Czosnyka M, Pena A, Pickard JD. Pattern of white matter regional cerebral blood flow and autoregulation in normal pressure hydrocephalus. Brain 2004; 127: 965-972.
31. Larsson A, Arlig A, Bergh AC, et al. Quantitative SPECT cisternography in normal pressure hydrocephalus. Acta Neurol Scand 1994; 90: 190-196.
32. Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H. Soluble amyloid precursor protein alpha in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. Eur J Neurol 2013; 20: 236-242.
33. Kapaki EN, Paraskevas GP, Tzerakis NG, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 2007; 14: 168-173.
34. Kitagaki H, Mori E, Ishii K, Yamaji S, Hirono N, Imamura T. CSF spaces in idiopathic normal pressure hydrocephalus: morphology and volumetry. AJNR Am J Neuroradiol 1998; 19: 1277-1284.
35. Tarnaris A, Toma AK, Chapman MD, et al. Rostrocaudal dynamics of CSF biomarkers. Neurochem Res 2011; 36: 528-532.
36. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chim Acta 2001; 310: 173-186.
37. Eriksdotter-Jonhagen M, Linderoth B, Lind G, et al. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 18-28.
38. Constantinescu R, Holmberg B, Rosengren L, Corneliusson O, Johnels B, Zetterberg H. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease. Acta Neurol Scand 2011; 124: 206-210.
39. Wikkelsø C, Blomstrand C. Cerebrospinal fluid proteins and cells in normal-pressure hydrocephalus. J Neurol 1982; 228: 171-180.